Data from Population-based Cancer Registration for Secondary Data Analysis: Methodological Challenges and Perspectives by Arndt, Volker et al.
Arndt V et al. Data from Population-based Cancer … Gesundheitswesen 2020; 82 (Suppl. 1): S62–S71
ThiemeReview Article 
Data from Population-based Cancer Registration for Secondary 
Data Analysis: Methodological Challenges and Perspectives
Daten bevölkerungsbezogener Krebsregister für die 




Volker Arndt1, 2, Bernd Holleczek3, Hiltraud Kajüter4, Sabine Luttmann5, Alice Nennecke6, Sylke Ruth Zeissig7,  
Klaus Kraywinkel8, Alexander Katalinic9, 10, 11
Affiliations
 1 Epidemiologisches Krebsregister Baden-Württemberg, 
Deutsches Krebsforschungszentrum, Heidelberg, 
Germany
 2 Deutsches Krebsforschungszentrum, AG Cancer 
Survivorship, Abt. Klinische Epidemiologie und 
Alternsforschung, Heidelberg, Germany
 3 Krebsregister Saarland, Saarbrücken, Germany
 4 Epidemiologisches Krebsregister NRW gGmbH, Bochum, 
Germany
 5 Leibniz-Institut für Präventionsforschung und Epidemi-
ologie - BIPS GmbH, Bremer Krebsregister, Bremen, 
Germany
 6 Behörde für Gesundheit und Verbraucherschutz (BGV), 
Hamburgisches Krebsregister, Hamburg, Germany
 7 Krebsregister Rheinland-Pfalz gGmbH, Mainz, Germany
 8 Robert Koch-Institut, Zentrum für Krebsregisterdaten 
(ZfKD), Berlin, Germany
 9 Universität zu Lübeck, Krebsregister Schleswig-Holstein, 
Institut für Krebsepidemiologie e.V., Lübeck, Germany
 10 Universität zu Lübeck, Institut für Sozialmedizin und 
Epidemiologie, Lübeck, Germany
 11 Gesellschaft epidemiologischer Krebsregister in 
Deutschland e.V. (GEKID e.V.), GEKID Working Group, 
Lübeck, Germany
Key words
cancer registration, epidemiology, secondary data, data 
quality, data sources
Schlüsselwörter





Gesundheitswesen 2020; 82 (Suppl. 1): S62–S71
© Georg Thieme Verlag KG Stuttgart · New York 
ISSN 0949-7013
Correspondence
PD Dr. Volker Arndt
Epidemiologisches Krebsregister Baden-Württemberg
Deutsches Krebsforschungszentrum





Population-based cancer registries have a long-standing role 
in cancer monitoring. Scientific use of cancer registry data is 
one important purpose of cancer registration, but use of cancer 
registry data is not restricted to cancer registries. Cancer reg-
istration in Germany is currently heading towards population-
based collection of detailed clinical data. This development 
together with additional options for record linkage and long-
term follow-up will offer new opportunities for health services 
and outcome research. Both regional population-based regis-
tries and the German Centre for Cancer Registry Data (ZfKD) 
at the Robert Koch-Institute as well as international cancer 
registries and consortia or organizations may provide external 
researchers access to individual or aggregate level data for sec-
ondary data analysis. In this review, we elaborate on the access 
to cancer registry data for research purposes, availability of 
specific data items, and options for data linkage with external 
data sources. We also discuss as well as on limitations in data 
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Introduction
Population-based cancer registries (PBCRs) have a long-standing 
and pivotal role in the fight against cancer. For many years, the 
focus of cancer registration had been on epidemiological surveil-
lance including trends and forecasting of cancer burden and on 
comparative studies on the variation of incidence and survival rates 
in time and place. PBCRs also play a crucial role in formulating can-
cer control plans, as well as in monitoring their success [1].
Scientific use of data collected by PBCRs is not limited to the re-
search staff of the PBCRs. PBCRs on the federal state level, the Ger-
man Centre for Cancer Registry Data (ZfKD) at the Robert Koch In-
stitute as well as international resources (details see below) may 
provide external researchers with individual or aggregate level data 
for secondary data analysis. In this review, we will elaborate on ac-
cess to PBCR data for research purposes, availability of specific data 
items, and options for data linkage with external data sources. The 
use of PBCR data for research purposes requires particular caution, 
however. Potential limitations in data availability and aspects of 
data quality will be addressed as well as specific biases which should 
be considered by any user of cancer registration data.
Population-based Cancer Registration in 
Germany
One of the first PBCRs in the world was established in Hamburg in 
the late 1920s. It was for many years the only one in Germany. After 
registration in Hamburg was stopped during the turmoil of World 
War II, the National Cancer Registry of the German Democratic Re-
public (East Germany) started operation in 1953. More than a dec-
ade later, the Saarland Cancer Registry was established in 1967. In 
the late 1970s, the Hamburg Cancer Registry was critically re-
viewed due to the emerging discussion of data privacy issues and 
completeness of registration dropped. Therefore, the Saarland Can-
cer Registry became the only internationally acknowledged PBCR 
in West Germany for several years and its data were used to approx-
imate cancer incidence in West Germany until the 1990s. The Ham-
burg Cancer Registry was reestablished in 1985 and the Münster 
registry in North Rhine-Westphalia was set up in 1986. The former 
National Cancer Registry (GKR) of the German Democratic Repub-
lic temporarily stopped operation due to changes in administration 
and legal basis during the process of the German reunification. The 
situation changed completely when a federal law on cancer regis-
tration (Krebsregistergesetz, KRG) [2] came into effect in 1995. All 
federal states were obligated by the KRG to set up PBCRs until 1999. 
As a result, coverage of PBCR constantly increased over the years 
and an increasing number of PBCRs has attained a high level of com-
pleteness (▶Fig. 1). The Federal Cancer Register Data Act (Bun-
deskrebsregisterdatengesetz, BKRG), which came into force in 
2009, obligated the federal states to ensure that the data from the 
PBCRs at the federal state level are collected comprehensively and 
transmitted in a uniform format to the Center for Cancer Registry 
Data (Zentrum für Krebsregisterdaten, ZfKD) at the Robert Koch-
Institute [3]. The ZfKD compiles a record set including cancer data 
collected by all PBCRs in Germany, which is used for national can-
cer monitoring as well as for scientific purposes.
In April 2013, the cancer detection and registration law (Kreb-
sfrüherkennungs- und -registergesetz, KFRG) [4] expanded the 
legal basis for cancer registration with respect to a nationwide uni-
form population-based clinical registration.
The consolidation of national data (e. g. German data pooled by 
the ZfKD) continues at the international level. At the European level, 
the European Network of Cancer Registries (ENCR) together with 
the Joint Research Center (JRC), a research institute of the Europe-
an Commission, is responsible for joint evaluations. Data from all 
cancer registries worldwide that meet certain quality criteria are 
compiled by WHO’s International Agency for Research on Cancer 
(IARC). IARC together with the International Association of Cancer 
Registries (IACR) publishes the report ‘Cancer Incidence in Five Con-
tinents’ (http://ci5.iarc.fr) every five years. In the first report of this 
series, which was published in 1966, Germany was represented by 
the Hamburg cancer registry only [5]. The national cancer registry 
of the former GDR was included in the second volume [6], the Saar-
land cancer registry in the third volume [7]. The current 11th volume 
covers the period 2008–2012 and lists nine registries from Germany 
(Bavaria, Bremen, Hamburg, Lower Saxony, Munich, North Rhine-
Westphalia, Rhineland-Palatinate, Saarland, Schleswig-Holstein) [8].
In addition to the above-mentioned PBCRs, which collect cancer 
cases in all age-groups, the German Childhood Cancer Registry 
(GCCR) has to be mentioned. The GCCR was founded in 1980. It is 
hosted by the Institute of Medical Biostatistics, Epidemiology and 
Informatics (IMBEI) at the University Medical Center of the Johannes 
Gutenberg University Mainz. It registers cancer cases for all children 
ZuSAmmeNFASSuNg
Bevölkerungsbezogene Krebsregister haben eine entschei-
dende Rolle in der Krebsbekämpfung. Die wissenschaftliche 
Verwendung von Krebsregisterdaten ist allerdings nicht allein 
den Krebsregistern vorbehalten. Die Krebsregistrierung in 
Deutschland entwickelt sich aktuell von einer primär epidemi-
ologischen Registrierung hin zu einer klinisch-epidemiologis-
chen Registrierung mit Erfassung detaillierter klinischer Daten. 
Diese Entwicklung zusammen mit weiteren Optionen für die 
Verknüpfung von Datensätzen und einer künftigen langfristi-
gen Nachbeobachtung bieten neue Möglichkeiten für die Ver-
sorgungs- und Gesundheitssystemforschung. Sowohl regionale 
bevölkerungsbezogene Krebsregister als auch das Zentrum für 
Krebsregisterdaten (ZfKD) am Robert Koch-Institut sowie in-
ternationale kollaborative Projekte und Dachorganisationen 
der Krebsregister können Wissenschaftlern Individualdaten 
oder aggregierte Daten für die Sekundärdatenanalyse bereit-
stellen. In dieser Übersichtsarbeit erläutern wir Zugangsmögli-
chkeiten zu Krebsregisterdaten, die Verfügbarkeit spezifischer 
Daten und Möglichkeiten der Verknüpfung der Registerdaten 
mit externen Datenquellen sowie mögliche Einschränkungen 
in Bezug auf Datenverfügbarkeit und Datenqualität wie auch 
typische Fehlerquellen bei Studiendesign und Datenanalyse.
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under 15 years (since 2009: under 18 years) in all of Germany. Since 
1991, children living in the area of the former GDR are included. The 
completeness of the GCCR for all over Germany is about 95 % and 
thus conforms to international requirements for a PBCR. About 1800 
cases are reported every year from pediatric oncology units affiliat-
ed at the Society for Paediatric Oncology and Haematology.
The current structures, the beginning of nationwide population-
based and clinical cancer registration, and the coverage rate of the 
PBCRs are shown in ▶table 1. It has to be mentioned that nowa-
days most PBCRs fulfill both population-based and clinical cancer 
registration (CCR) in one organization, so that the distinction be-
tween PBCR and CCR primarily reflects different kinds/perspectives 
of data usage rather than processes of cancer registration. Howev-
er, this does not hold for hospital-based cancer registries, which 
only collect information on cancer patients treated in the institu-
tion concerned.
What Data are Available in Population-based 
Cancer Registries in Germany?
Statewide operating PBCRs collect data on invasive malignant ne-
oplasms, their preliminary stages as well as neoplasms of uncertain 
or unknown behavior and benign neoplasms of the central nervous 
system. Non-melanoma skin cancer is an exception because the 
registration of these tumors is not mandatory in all federal states 
and the amount of collected information varies across the states.
Traditionally, PBCRs collect data for patients living in the geo-
graphical catchment area of the PBCR, irrespective of place of di-
agnosis, treatment or death. The data contain personal identifiers, 
demographic items, information about the tumor including stage, 
site and extent of disease at the date of diagnosis as well as follow-
up information of the patient including vital status and date and 
cause of death (▶table 2) [9, 10].
In contrast, new comprehensive clinical cancer registries accord-
ing to the KFRG collect data of all patients treated in the assigned 
area of the CCR irrespective of place of residence [3]. In addition to 
the data items captured by PBCRs, these CCRs record information 
about the specific treatment provided, disease trajectories, and ad-
ditional tumor specific items relevant for the classification of the 
tumor. The data collected by these comprehensive CCRs are de-
fined by a common catalogue of items (so called ‘ADT/GEKID Core 
data set’ [ADT/GEKID-Basisdatensatz] and additional tumor spe-
cific modules) [11–14]. The collection of these items is mandatory 
for all CCRs in Germany, which operate on a statutory basis. As men-
tioned above, most PBCRs in Germany are now responsible for both 
population-based and clinical cancer registration.
No Data
< 70 %
70 % – < 80 %
80 % – < 90 %
≥ 90 %
11953 East-Berlin, 1995 Berlin (re-united)
21986 Münster administrative district,
  2005 all North Rhine-Westphalia
32003 Darmstadt administrative district,




































▶Fig. 1 Development of the estimated completeness of the population-based cancer registries in Germany 2000/2002 and 2014 by federal state 
or region (showing start of registration) [29].
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One of the major limitations of data currently collected by PBCRs 
is that information on comorbidities, important risk factors like 
smoking or occupational hazards, data on quality of life or socio-
economic status are not routinely collected. This limitation is based 
on the fact that a valid and complete documentation is not feasi-
ble in daily clinical routine. Also, genetic information of the tumors 
or links to biobank data, which are of utmost interest in the era of 
personalized medicine and which might provide further insight in 
the tumorigenesis, are not collected. But linkage of PBCR data with 
data from other sources to address specific research questions is 
possible (details see below).
Cancer Registration Data for Secondary Data 
Analysis
In principle, several different ways to access and use cancer regis-
try data have to be distinguished:
1. Aggregated data
2. Anonymized individual data
3. Cohort linkage
4. Individual patient access
Aggregated data
Individual data based on selected characteristics are aggregated 
into groups e. g. defined by year of incidence, age and sex. For the 
resulting groups, different indicators such as the number of peo-
ple in the relevant group and the incidence rate may be reported. 
Aggregated data may be used for trend analysis, regional compar-
isons, e. g. based on regional socio-economic or geophysical indi-
ces. The only legal requirement is that no individual can be identi-
fied from the data set provided to the external researcher.
Aggregated national and international data on incidence, mor-
tality, survival or prevalence are available on interactive websites 
(▶table 3). In addition, many state-level PBCRs listed in ▶table 1 
already provide aggregate level statistics on their websites. These 
resources usually include age-standardized and age-specific rates 
(in 5-year age groups) by sex, cancer, year, and geographical region 
(if applicable).
Provision of aggregated data usually follows a standard format 
(i. e. predefined age and tumor categories). For rare diagnoses, sub-
types or tumor stage distribution, provision of aggregated data is 
possible on request. The individual PBCR or the ZfKD, respectively, 
approve specific data requests on the basis of feasibility, validity 
and completeness of the data, data privacy aspects, data thrift, and 
▶table 1 Structure of population-based and clinical cancer registration in Germany by state









Baden-Württemberg Integrated CCR/PBCR with distinct TC, RO, and PBCR 2009 2009 11,0  ≥ 90 %
Bavaria Integrated CCR/PBCR based on 6 regional 
registration units
1998 2017 13,0  ≥ 90 %
Brandenburg CCR (in conjunction with Berlin) based on several 
regional RO; PBCR via GKR
1953 1953 2,5  ≥ 90 %




3,6 70 % – < 80 %
Bremen Integrated CCR/PBCR with consolidated TC and RO 1998 2015 0,7  ≥ 90 %
Hamburg Integrated CCR/PBCR with consolidated TC and RO 1926 2014 1,8  ≥ 90 %
Hesse Integrated CCR/ECT with TC and RO 2007 2014 6,2 70 % – < 80 %
Mecklenburg-West Pomerania CCR with TC and RO; PBCR via JCR/GKR 1953 1953 1,6  ≥ 90 %
Lower Saxony Distinct CCR and PBCR with mutual TC 2000 2017 8,0  ≥ 90 %
North Rhine-Westphalia Integrated CCR/PBCR with TC and RO 2005 2016 17,9  ≥ 90 %
Rhineland-Palatinate Integrated CCR/PBCR with TC and RO 1997 2016 4,1 80 % – < 90 %
Saarland Integrated CCR/PBCR with TC and RO 1967 2015 1,0  ≥ 90 %
Saxony State CCR based on 4 regional CCR; PBCR via GKR 1953 1953 4,1  ≥ 90 %
Saxony-Anhalt State CCR based on 3 regional RO; PBCR via GKR 1953 1953 2,2 70 % – < 80 %
Schleswig-Holstein Integrated CCR/PBCR with TC and RO 1998 2016 2,9  ≥ 90 %
Thuringia State CCR based on 5 regional RO; PBCR via GKR 1953 1953 2,2  ≥ 90 %
Joint Cancer Registry (JCR/GKR) of 
Berlin, Brandenburg, Mecklenburg-
West Pomerania, Saxony, 
Saxony-Anhalt and Thuringia
PBCR for 6 federal states (former GDR)  
with TC and RO
1953 – 16,2 see state  
specific details
German Childhood Cancer 
Registry (GCCR)
Nationwide PBCR/CCR for children under 15 years 
(since 2009: under 18 years) in all of Germany
1980 1980 13,5 95 %
Abbreviations: CCR Clinical Cancer Registry; PBCR Population-based Cancer Registry; GDR German Democratic Republic; GKR Gemeinsames Krebsreg-
ister (Joint Cancer Registry of Berlin, Brandenburg, Mecklenburg-Vorpommern, Saxony, Saxony-Anhalt and Thuringia); RO Registration Office; TC Trust 
Center. * Start of statewide registration based on state specific legislation; * * Completeness based on estimates by German Centre for Cancer Registry 
Data (ZfKD) regarding all cancer sites combined (ICD-10: C00-C97 excl. C44)[29].
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required resources. Service fees may be charged depending on re-
quired resources. If more complex evaluations are required for sci-
entific purposes, the option of a scientific collaboration project 
should be considered.
Anonymized individual data
For specific purposes, anonymized individual data can be provided 
by PBCRs to external researchers. Individual features might be omit-
ted or collapsed in broader categories in order to preclude re-iden-
tification of individual persons and to follow the concept of data 
thrift. Access to anonymized individual level data from state can-
cer registries and from the national data set is regulated in state-
specific PBCR legislation and in the Federal Cancer Registry Data 
Act (BKRG), respectively. The list of available data is usually limited 
to general information about the individual (age, sex and place of 
residence), data on tumor diagnosis (ICD-10, tumor site, histology, 
tumor stage and classification, date of diagnosis, diagnostic basis), 
and survival time.
Requests for access to anonymized individual data should usu-
ally include the formulation of a research question, a description 
of the planned evaluation methods and a comprehensible listing 
of the required variables (under consideration of data thrift) and 
the definition of inclusion and exclusion criteria. In some states, the 
research projects have to fulfill certain requirements, e. g. the Ham-
burg Cancer Registry Act requires that the planned project contrib-
utes to the “improvement of cancer prevention or cancer control”. 
Similar requirements, which explicitly demand a public interest in 
the anticipated research results, are also found in other state laws. 
Prior to the formal application, it is generally recommended to con-
tact the registries or the ZfKD in advance in order to clarify specif-
ic details and the feasibility of the planned research project.
Cohort linkage
The third possibility is to link individual data of an external cohort 
(e. g. diabetics enrolled in a statutory health insurance care plan) 
with the data stored in the cancer registry (e. g. [15]). Linkage for 
large scale cohort studies is usually applied on encrypted data using 
a pseudonymization key based on name, gender, date of birth, and 
place of residence. This method has been well established and was 
evaluated in the early 1990s [16, 17]. In general, the identity data 
of the study participants who have agreed to the cohort linkage 
are transmitted together with a study ID to the trust center of the 
▶table 2 Individual level data items available in population-based and clinical cancer registries in Germany
Data group Items in PBcR and ccR Items only in ccR
Identity data * – Name
– Address
– Date of birth
– Health insurance number
Notification * –  Name of notifying institution/
professional
– Date of receipt
– Patients objection
Demographic data – Age
– Year of birth
– Area of residence
Tumor data at time 
of diagnosis





–  Stage of disease (TNM, UICC,  
other classifications)
– Date of histological report
– Number of (sentinel-) lymph nodules explored and positive for cancer
– Distant metastasis (date and location)
– Performance status of the patient
–  Additional markers for special cancer entities according to national guidelines (e. g. 
HER-2 status, hormon receptor status, tumor size in mm, Gleason-Score, KRAS-Gen 
and other)
Treatment data – Operation (Yes/No)
– Chemotherapy (Yes/No)
– Radiotherapie (Yes/No)
– Hormone therapy (Yes/No)
– Immune therapy (Yes/No)
–  Bone marrow transplantation  
(Yes/No)
– Kind of therapy
– Intention of therapy
– Relation to surgery
– Date of begin/end
– Complications/ side effects
– Surgery OPS-Code
– Radiotherapy target area, type of application, single and total radiation dose
– Chemotherapy protocol and substances,
– Additional items for special cancer entities according to national guidelines
Disease trajectory – Vital status – Residual status after primary therapy
– Disease status: progression/ recurrence of disease
Death – Date of death
– Causes of death
– Death caused by tumor
Other data – Tumor conference (date)
– Additional items for special cancer entities: social service contact, study participation
PBCR = Population-based cancer registries. CCR = Clinical cancer registries. * Limited data access only under special preconditions (patients’ consent).  
* * Active surveillance of patients only in some CCR.
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PBCR. The trust center converts the identity data into unique to-
kens (“pseudonymization”) similar to the procedure applied for 
routine case notifications. These tokens are then compared with 
the tokens already present in the registry using probabilistic link-
age. In case of matching tokens, the corresponding internal regis-
try case number and the study ID are transmitted to the registra-
tion office. After successful linkage with the desired information 
from the cancer registry, the data are transmitted to the research 
institution without disclosing the identity of the patients.
This type of probabilistic record linkage is not error free; and so 
called ‘homonym errors’ (linkage of data pertaining to two distinct 
case) and ‘synonym errors’ (disaggregation of data pertaining to 
one case) may occur [18, 19]. Nevertheless, an evaluation study 
showed that this technique is able to process large amounts of data 
with very high quality of record linkage [20].
Deterministic record linkage via social security number is a 
standard method in studies using data from Scandinavian registries 
but is not yet established in Germany. However, this will also be 
possible in Germany in future years for around 90 % of the popula-
tion as cancer registries are now required (by KFRG) to record the 
health insurance number of patients enrolled in statutory health 
insurance plans. The quality of these numbers requires attention 
as mistyping due in case of manual entry may occur.
A special case of cohort linkage arises in the evaluation of organ-
ized screening programs [21]. Here, participants in screening pro-
grams will be linked on the basis of legal regulations with data from 
the cancer registry to identify interval cancers (i. e. discovered be-
tween two screening rounds).
Provision of individual data for specific individuals in the context 
of cohort studies (‘cohort linkage’) usually requires the correspond-
ing consent of the individual and approval by ethics committee. In-
dividual patient consent should ideally be obtained in advance by 
the study in question at recruitment or during follow-up. Some 
states (e. g. Rhineland-Palatinate) offer the possibility of cohort 
linkage without the necessity of individual consent under the con-
dition of strict separation of personal identifiers and medical data. 
In some registries (e. g. Baden-Württemberg) no informed consent 
is required if only information on date and cause of death is trans-
mitted. Cohort linkage is only possible at PBCRs but not at the ZfKD. 
As a consequence, a nationwide cohort linkage requires separate 
linkages with all PBCRs in Germany.
Individual patient access
Direct (by name) access to individual data stored in the registers, 
e. g. for interviews or examinations of patients as part of a case-
control study, is only possible with informed consent of the patient 
in accordance with the state-specific regulations of the registry and 
under the precondition, that the patient did not veto the storage 
of the encrypted name beforehand.
For studies requiring individual patient access, e. g. for recruit-
ing cases within a case-control study, approval by the responsible 
ethics committee and/or advisory board, the cancer registry or its 
regulatory body (government department) is required. In most 
federal states, after approval of the study protocol, patients will be 
initially contacted by cancer registry or the reporting physicians to 
obtain patients’ consent to be contacted by the research group for 
this specific research project. Once this has taken place, the names 
and addresses of the patients can be forwarded to the research 
group for further contact. Again, the state- specific requirements 
may vary, e. g. the cancer registration act of North Rhine-Westphal-
ia requires that the financing of the planned project has to be se-
cured and disclosed before access to individual patients can be 
granted.
Data Quality Aspects
The value of the cancer registration data to contribute to cancer 
control and research relies heavily on the underlying quality of its 
data and the quality control procedures in place. Key aspects of 
data quality with respect to cancer registration data include com-
parability, validity, timeliness, and completeness [22, 23].
comparability is the extent to which coding and classification 
procedures at a registry, together with the definitions of recording 
and reporting specific data items, adhere to agreed international 
guidelines [22]. A basic requirement is the standardization of prac-
tices concerning classification and coding of new cases, and con-
sistency in basic definitions of incidence, such as rules for the re-
cording and reporting of multiple primary cancers occurring in the 
same individual [9, 10].
Validity is defined as the proportion of cases in the registry with 
a given characteristic (e. g. cancer site, or age) which truly have this 
attribute [24]. Validity is examined via numerical indices which are 
either compared with other registries, or, within a registry, over 
time, or with respect to specified subsets of cases [22]. Common 
indicators of validity are the percentage of histologically verified 
(HV) cases as statement on the diagnostic accuracy, the propor-
tion of DCO (case information based on ‘death certificate only’), 
and the percentage of unknown or ill-defined primary site (PSU) 
due to missing information. Of high priority are continuous inter-
nal consistency checks that look for impossible codes and implau-
sible combinations of different variables in the same record. Plau-
sibility testing according to international and national rules 
[10, 25, 26] is routinely performed by means of electronical pro-
cesses as well as manual editing.
timeliness with regard to cancer registration defines the time 
span between the notifiable disease event and its publication with-
in health reporting. There are no international guidelines for time-
liness at present [22], but a recent survey among European cancer 
registries indicated wide variation regarding latency for complet-
ing 1 year of case ascertainment and releasing data to the public 
[27]. Physicians in Germany are required to submit their case noti-
fications to the corresponding CCR within a range of four weeks to 
6 months, depending state specific regulations. The CCRs are itself 
required to process and check all new incoming case notifications 
within a maximum of 6 weeks. By end of 2017, 6 out of 17 clinical 
cancer registries fulfilled this criteria [28].
According to the Federal Cancer Registry Data Act [3], German 
cancer registries have to submit their data to ZfKD within 2 calen-
dar years after the year of diagnoses. Another aspect of actuality 
involves the completion of mortality follow-up. The processing of 
death certificates provided by local health authorities and the col-
lection of vital status information from the residents’ registration 
office may require up to two years.
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completeness is usually defined as the extent to which all of the 
incident cancers occurring in the population are included in the 
registry database [23]. It is also called completeness of coverage 
in order to distinguish it from item completeness, which corre-
sponds to the availability of complete information regarding spe-
cific data item such as information regarding stage, treatment etc.
completeness of coverage of German PBCRs is regularly as-
sessed by the ZfKD. For this purpose, log-linear models are used 
assuming a largely constant mortality to incidence ratio (M: I) for 
certain cancers, age groups, sex, and calendar years across Germa-
ny. The estimated degree is equal to the ratio of observed and ex-
pected case figures accumulated across all age groups. The results 
are published within the joint publication of “Cancer in Germany” 
[29] by GEKID and the ZfKD, with 90 % being rated as sufficiently 
complete.
A high level of item completeness (data accuracy) means that 
all notifiable details concerning a case and its course of disease are 
recorded. Availability and completeness of the collected data de-
pend on the ‘age’ of the particular PBCR. As described earlier, most 
German PBCRs were set up around the turn of the millennium. Yet 
for some regions, continuous data are available for longer time pe-
riods. Currently most of the German PBCRs present highly satisfac-
tory information content on personal data, diagnoses, and vital 
status. On the other hand, the proportion of sufficient stage infor-
mation varies widely between registries, cancer types, and years 
of diagnosis. As statewide clinical cancer registration was initiated 
in 2013, most CCRs are still in the build-up phase and have not yet 
attained sufficient item completeness regarding certain clinical fea-
tures such as treatment information and course of disease [28]. 
Standard techniques and criteria regarding target values for cer-
tain variables are currently discussed. When planning a research 
project, the requestor should contact the CCR beforehand in order 
to clarify for which time period is sufficiently complete clinical data 
is available. In some regions, e. g. in Bavaria or Brandenburg, CCRs 
▶table 4 Examples of potential biases in the use of cancer registration data




bias (or Neyman 
Bias or „Survival 
Bias”)
Occurs when the estimation of the risk of a disease is made 
by using data collected at a given point in time in a series of 
survivors (rather than being based on data collected during 
a time period). → Selection bias where the very sick or very 
well (or both) are erroneously excluded from a study.
Return to work rate in long-term 
cancer survivors [32]
Careful selection of study 
type: Prospective cohort 





Occurs when the indication to treat is a confounder for the 
treatment-outcome relationship.
Assessing treatment effects in older 
breast cancer patients [33]
Controlling statistically 
for known confounders 
related to the indication.
Immortal time 
bias
Occurs in cohort studies when a period of ‘immortal time’ 
(time during which death or an outcome that determines end 
of follow-up cannot occur) is excluded from the analysis, e. g. 
the start of follow-up for the group receiving “new” 
treatment is defined by the start of the new treatment, which 
is later than that for the comparison group.
Beta blockers and cancer prognosis 
[34]
Using time-fixed analysis 
with exclusion of immortal 
time and adjustment for 
confounders at baseline 
and/or during follow-up 
periods.




Risk of disease sequelae may be affected when multiple risk 
factors for sequelae (e. g. mortality) are also risk factors for 
having the disease in the first place (“collider”). 
Obesity paradox in survival after 
cancer diagnosis [35]
Avoid stratification/
control of a collider.
Lead-time bias Overestimation of survival time, due to the backward shift 
in the starting point for measuring survival when follow-up 
of groups does not begin at comparable stages in the 
natural history of a condition.
Apparent increase in survival of 
patients if screening merely 
advances diagnosis without 
increasing chances of cure [36]




Apparent survival advantage of screen-detected cases due 
to an oversampling of slowly growing tumors by screening, 
particularly in case of long screening intervals. 
Apparent superior overall survival in 
women with asymptomatic 
recurrence of early stage endome-
trial cancer compared to sympto-
matic recurrence [37]
Count all outcomes in 




Compliant patients tend to have better prognosis regardless 
of screening and might be overrepresented in screening 
programs.
Assessment of overdiagnosis due to 
mammography screening by 
comparing attendees of a screening 
program with those not attending 
[38–39]
Compare outcome in 
RCT with control group 





Significant differences in patient, tumor and/or treatment 
related characteristics between registered and non-regis-
tered patients lead to incomparable results.
Assessment of completeness and 
registration bias in a cancer cohort 
with participation on a voluntary 
basis [40]
Registration on a 
mandatory basis, quality 
assessment of complete-
ness of registered data.
Information bias 
due to record 
linkage errors
Errors in the record linkage: 
–  Homonym error (linkage of data pertaining to two 
distinct case)
–  Synonym error (disaggregation of data pertaining to one case)
Cohort linkage, comparison of 
incidence and survival rates 
between registries [41]
Exclude registries with 
high DCO rates or 
extreme incidence rates.
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were already established in the 1990s, so that longer time series of 
clinical data might be available.
Evaluation of data quality prior to analysis is a critical issue for 
sound analysis, unbiased results, and meaningful interpretation. 
Guidelines for the use of data quality criteria and their reporting 
have been exemplarily described by the GEKID Cancer Survival 
Group [30, 31].
In addition to data quality issues, bias in design and analysis 
might also imperil proper analysis and interpretation of cancer reg-
istration data. ▶table 4 lists some potential specific and general 
examples of biases which may occur in the use of cancer registra-
tion data. This list is neither exhaustive nor specific to the use of 
cancer registration data in secondary data analysis. It reflects real-
world examples from the literature or from previous data requests.
Summary and Outlook
Cancer registries are a vital source of information on cancer epide-
miology and cancer care. As cancer registration in Germany is mov-
ing towards population-based registration of detailed clinical data, 
evaluation of quality of care is becoming a new task. This develop-
ment, together with additional options for record linkage (e. g. via 
health insurance number) and long-term follow-up, will offer new 
opportunities for health services and outcome research. Informa-
tion coming from genome-wide association studies are currently 
not included in PBCRs but genomic data will play a pivotal role in 
future understanding of carcinogenesis, drug effectiveness, drug 
resistance, and occurrence of side effects. Regulations are required 
on how to enable data collection of cancer patients’ genetic pro-
files and/or linking with available biobanks. In summary, data from 
German PBCRs have a high potential for scientific use and the op-
tions for their use within secondary data analysis have substantial-
ly improved in recent years.
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